EnSite to enter US trial for left atrial use:
This article was originally published in Clinica
Executive Summary
Endocardial Solutions is to begin a US clinical trial to assess its EnSite 3000 three-dimensional mapping system as a means of diagnosing arrhythmias, including atrial fibrillation, in the left atrium of the heart. The trial is expected to start in the second quarter of 2001 and will include up to eight institutions in the US and Canada, says the St Paul, Minnesota company. The product was cleared by the FDA for use in the right atrium in 1999. It is also available in Europe for right atrial and left ventricular use.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.